Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    19917835 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma
Condition: Unresectable Stage III or Stage IV Melanoma
Interventions: Biological: Ofatumumab;   Biological: Ofatumumab plus Dacarbazine
2 Not yet recruiting Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: Cobimetinib

Indicates status has not been verified in more than two years